The role
of adjuvant systemic therapy in patients with mucosal melanoma following definitive therapy is not clear.
Not exact matches
The HZI will develop a vaccination protocol for mucosal administration based on three novel strategies: (i) development and optimization
of a vaccination protocol in which parenterally - primed T and B cells are subsequently pulled into the mucosa by the local delivery
of the cognate antigen to the requested effector site, (ii) testing the co-administration
of antigens with novel mucosal
adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both
systemic and mucosal immune responses following transcutaneous / trans - follicular vaccination.
Inclusion Criteria: • The participant may have no more than 2 prior lines
of systemic therapies (neoadjuvant and
adjuvant therapies will not be considered as a prior line
of therapy) for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.
Oncotarget, 8: 67626 - 67638, 2017 S.S. Immune
adjuvant activity
of pre-resectional radiofrequency ablation protects against local and
systemic recurrence in aggressive murine colorectal cancer.